S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Elon Musk Sees Serious Crisis (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Elon Musk Sees Serious Crisis (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
Elon Musk Sees Serious Crisis (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Elon Musk Sees Serious Crisis (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Elon Musk Sees Serious Crisis (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
Elon Musk Sees Serious Crisis (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Elon Musk Sees Serious Crisis (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Elon Musk Sees Serious Crisis (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
Elon Musk Sees Serious Crisis (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Elon Musk Sees Serious Crisis (Ad)
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Elon Musk Sees Serious Crisis (Ad)
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
Elon Musk Sees Serious Crisis (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
NASDAQ:CLSD

Clearside Biomedical - CLSD Stock Forecast, Price & News

$1.18
+0.03 (+2.61%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.12
$1.22
50-Day Range
$1.05
$1.49
52-Week Range
$1.00
$3.38
Volume
107,728 shs
Average Volume
274,691 shs
Market Capitalization
$71.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60

Clearside Biomedical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
544.1% Upside
$7.60 Price Target
Short Interest
Healthy
1.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$39,900 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.52) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

771st out of 1,022 stocks

Pharmaceutical Preparations Industry

376th out of 499 stocks

CLSD stock logo

About Clearside Biomedical (NASDAQ:CLSD) Stock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Stock News Headlines

JMP Securities Reaffirms Their Buy Rating on Clearside Biomedical (CLSD)
Texas Academy of Biomedical
See More Headlines
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Company Calendar

Last Earnings
11/10/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSD
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.60
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+544.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$380,000.00
Pretax Margin
-17.15%

Debt

Sales & Book Value

Annual Sales
$29.58 million
Cash Flow
$0.01 per share
Book Value
$0.64 per share

Miscellaneous

Free Float
52,968,000
Market Cap
$71.02 million
Optionable
Optionable
Beta
1.84

Key Executives

  • Dr. George M. Lasezkay J.D.Dr. George M. Lasezkay J.D. (Age 70)
    Pharm.D., Pharma.D., Pres, CEO & Director
    Comp: $836k
  • Mr. Charles A. DeignanMr. Charles A. Deignan (Age 58)
    Chief Financial Officer
    Comp: $510.81k
  • Dr. Thomas A. Ciulla M.B.A. (Age 58)
    M.D., Chief Medical Officer & Chief Devel. Officer
    Comp: $589.77k
  • Ms. Jenny R. Kobin (Age 55)
    Head of Investor Relations
  • Mr. Rick McElheny
    VP of Corp. Devel.
  • Ms. Susan L. Coultas Ph.D.
    Chief Clinical Officer
  • Mr. Leslie B. Zacks (Age 53)
    Sec.













CLSD Stock - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings
or view top-rated stocks.

What is Clearside Biomedical's stock price forecast for 2023?

5 analysts have issued 12 month target prices for Clearside Biomedical's shares. Their CLSD share price forecasts range from $5.00 to $10.00. On average, they predict the company's stock price to reach $7.60 in the next twelve months. This suggests a possible upside of 544.1% from the stock's current price.
View analysts price targets for CLSD
or view top-rated stocks among Wall Street analysts.

How have CLSD shares performed in 2022?

Clearside Biomedical's stock was trading at $2.75 at the start of the year. Since then, CLSD stock has decreased by 57.1% and is now trading at $1.18.
View the best growth stocks for 2022 here
.

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our CLSD earnings forecast
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $3.07 million for the quarter, compared to analysts' expectations of $3.32 million. Clearside Biomedical had a negative net margin of 17.15% and a negative trailing twelve-month return on equity of 16.13%. During the same quarter last year, the firm earned ($0.05) earnings per share.

What other stocks do shareholders of Clearside Biomedical own?
When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional investors include ACT Capital Management LLC (3.65%), BlackRock Inc. (1.98%), Renaissance Technologies LLC (1.09%), Assenagon Asset Management S.A. (0.68%), Two Sigma Advisers LP (0.37%) and Two Sigma Investments LP (0.28%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.18.

How much money does Clearside Biomedical make?

Clearside Biomedical (NASDAQ:CLSD) has a market capitalization of $71.03 million and generates $29.58 million in revenue each year. The company earns $380,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The official website for the company is www.clearsidebio.com. The company can be reached via phone at (678) 270-3631, via email at charlie.deignan@clearsidebio.com, or via fax at 678-270-4033.

This page (NASDAQ:CLSD) was last updated on 12/9/2022 by MarketBeat.com Staff